Stock AnalizPharvaris N.V. PHVS
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Pharvaris N.V. (PHVS) is a healthcare company listed in the US with a market value of about $2.3B.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -33%.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Net income | -$206M | -$139M | -$111M | -$81M | -$48M | -$26M | -$8M | -$4M |
| Free cash flow | -$161M | -$125M | -$103M | -$72M | -$51M | -$26M | -$8M | -$4M |
| EPS (diluted) | $-2.96 | $-2.00 | $-1.60 | $-1.17 | $-0.69 | $-0.37 | $-0.12 | $-0.06 |
| Net margin | — | — | — | — | — | — | — | — |
| ROIC | -50.6% | -39.1% | -20.5% | -40.0% | -16.4% | -27.1% | -43.0% | -87.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Pharvaris pay a dividend?
Not currently.
Is Pharvaris a good stock to buy?
We do not give buy or sell advice. Pharvaris scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.